Results 151 to 160 of about 1,208,918 (256)

Stabilisation of PRCP by deubiquitinase‐targeting chimera (DUBTAC) to replenish autophagy for ameliorating pathological cardiac hypertrophy

British Journal of Pharmacology, Volume 182, Issue 21, Page 5317-5339, November 2025.
Background and Purpose Autophagy is essential for cellular homeostasis, and its impairment contributes to cardiac hypertrophy. Modulating autophagy has shown potential in treating pathological hypertrophy. Prolylcarboxypeptidase (PRCP), a lysosomal enzyme that hydrolyzes angiotensin II to Ang1‐7, has an unclear role in cardiac autophagy and hypertrophy.
Fangchao Zhou, Jun Xia, Yingjuan Liu, Wenqi He, Hongyuan Zhang, Bernard D. Keavney, Min Zi, Binh Y. Nguyen, Tamer M. A. Mohamed, Jessica M. Miller, Riham R. E. Abouleisa, Susanne S. Hille, Elizabeth J. Cartwright, Oliver J. Müller, Honglin Xu, Sam Butterworth, Xin Wang   +16 more
wiley   +1 more source

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

Cell Proliferation, Volume 58, Issue 11, November 2025.
CRISPR‐Cas systems offer transformative genome editing capabilities for precise manipulation of cellular genes. This enables two main therapeutic avenues: ex vivo modification of patient cells for re‐transplantation or direct in vivo gene targeting via advanced delivery methods.
Bahareh Farasati Far, Marziyeh Akbari, Mohammad Amin Habibi, Morteza Katavand, Sherko Nasseri   +4 more
wiley   +1 more source

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor‐Mediated Drug‐Induced Liver Injury Using a Liver‐On‐Chip Model

Clinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT Elexacaftor/tezacaftor/ivacaftor (ETI), a cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, has provided great improvements in lung function and well‐being for people with CF. The use of ETI has been complicated by reports of rare but significant liver function test elevations in clinical trials and drug‐induced ...
Alan Shi, Palak Agarwal, Zhang‐Xu Liu, Paul M. Beringer   +3 more
wiley   +1 more source

Personalised medicine of Cystic fibrosis [PDF]

, 2017
Treballs Finals de Grau de Farmàcia, Facultat de Farmàcia, Universitat de Barcelona, 2017. Tutor: Carlos Julián Ciudad i Gómez[en] The European commission defines personalised medicine as a medical approach that uses molecular insights into health and ...
Cabré Juan, Antoni
core  

CFTR modulators: from mechanism to targeted therapeutics [PDF]

People with cystic fibrosis (CF) suffer from a multi-organ disorder caused by loss-of-function variants in the gene encoding the epithelial anion channel cystic fibrosis transmembrane conductance regulator (CFTR).
Hwang, Tzyh-Chang, Sheppard, David N, Sutcliffe, Katy, Yeh, Han-I   +3 more
core   +1 more source

MetaNeb Versus Usual Care During Exacerbations of Cystic Fibrosis: An RCT

Respirology, Volume 30, Issue 11, Page 1046-1055, November 2025.
In adults with cystic fibrosis who were hospitalised with an exacerbation, twice daily MetaNeb produced greater improvements in ventilation inhomogeneity compared to twice daily usual airway clearance techniques. There were no between‐group differences shown for other outcomes, including respiratory symptoms.
Naomi Chapman, Vinicius Cavalheri, Elizabeth F. Smith, Jamie Wood, Luke W. Garratt, Siobhain Mulrennan, Anne Smith, Anna S. Tai, Kylie Hill   +8 more
wiley   +1 more source

Citrus Flavonoids for Cystic Fibrosis Treatment

ChemBioChem, Volume 26, Issue 20, October 31, 2025.
Studies conducted since the late 1990s show substantial activity of selected citrus flavonoids as cystic fibrosis transmembrane conductance regulator (CFTR) membrane protein activators. The thesis of this work is that aptly formulated citrus flavonoids hold sigificant potential for developing a multitarget treatment of cystic fibrosis combining in a ...
Mario Pagliaro, Caterina Di Sano, Claudia D'Anna, Giovanna Li Petri, Giuseppe Angellotti, Rosaria Ciriminna   +5 more
wiley   +1 more source

Clinically approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia [PDF]

, 2019
Dana C. Borcherding, Matthew Siefert, Songbai Lin, John J. Brewington, Hesham A. Sadek, John P. Clancy, Scott M. Plafker, Assem Ziady   +7 more
openalex   +1 more source

New Mechanisms for Regulation of Intracellular Collagen Degradation in Fibrotic Lesions of Periodontal Tissues

The FASEB Journal, Volume 39, Issue 20, 31 October 2025.
Drug‐induced gingival overgrowth involves dysregulation of intracellular collagen degradation. The mechanisms that are involved in the regulation of lysosomal collagenolytic activity are poorly understood. Here, we focus on how cathepsins, Rabs, and V‐ATPases regulate intracellular collagen degradation and, in particular, the vesicular trafficking and ...
Wing Hei Wong, Ralph A. Zirngibl, Morris F. Manolson, Christopher A. McCulloch   +3 more
wiley   +1 more source

In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets

JCI Insight
Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, with F508del being the most prevalent mutation.
Idil Apak Evans, Xingshen Sun, Bo Liang, Amber R. Vegter, Lydia Guo, Thomas J. Lynch, Yan Zhang, Yulong Zhang, Yaling Yi, Yu Yang, Zehua Feng, Soo Yeun Park, Amanita Shonka, Hannah McCumber, Lisi Qi, Peipei Wu, Guangming Liu, Allison Lacina, Kai Wang, Katherine N. Gibson-Corley, David K. Meyerholz, Dominique H. Limoli, Bradley H. Rosen, Ziying Yan, Douglas J. Bartels, John F. Engelhardt   +25 more
doaj   +1 more source